HOME >> MEDICINE >> NEWS
FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS

Phase III trials at one year demonstrate new level of efficacy 66% reduction in rate of relapses seen in AFFIRM monotherapy trial

Cambridge, MA; San Diego, CA; Dublin, Ireland November 23, 2004 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the U.S. Food and Drug Administration (FDA) has approved TYSABRI (natalizumab), formerly referred to as ANTEGREN, as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses. FDA granted Accelerated Approval for TYSABRI following Priority Review based on one-year data from two Phase III studies, the AFFIRM monotherapy trial and the SENTINEL add-on trial with AVONEX(Interferon beta-1a).

TYSABRI, the first humanized monoclonal antibody approved for the treatment of MS, inhibits adhesion molecules on the surface of immune cells. Research suggests TYSABRI works by preventing immune cells from migrating from the bloodstream into the brain where they can cause inflammation and potentially damage nerve fibers and their insulation.

"TYSABRI is a powerful and innovative therapy that offers new hope for hundreds of thousands of people living with MS," said James C. Mullen, chief executive officer, Biogen Idec. "We believe TYSABRI will revolutionize the treatment of MS and become the leading choice for patients and physicians."

"TYSABRI is a significant breakthrough for patients with MS," said Kelly Martin, president and chief executive officer, Elan. "The approval of TYSABRI, with its unique mechanism of action and new level of efficacy, has the potential to make a genuine difference in the lives of patients and families who struggle with the debilitating effects of this disease."

Results of the AFFIRM Monotherapy Trial

AFFIRM is a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients conducted in 99 sites worldwide, in which patients were
'"/>

Contact: Amy Losak
646-935-9317
Ketchum
23-Nov-2004


Page: 1 2 3 4 5 6

Related medicine news :

1. UNH launches 2nd spinout company with NIH grants
2. Disease testing for immigrants: Discrimination disguised as public health policy
3. US FDA grants full approval to DOXIL(R) following submission of phase III data
4. Four teams awarded inaugural translational cancer research grants
5. Immigrants, beware: Living in the United States is fattening
6. Prevalence of obesity among immigrants increases with longer residency in US
7. Dana-Farber receives CDC grants to develop health promotion/prevention programs in the work place
8. Speech recognition experts at OGI School of Science & Engineering receive nearly $700,000 in grants
9. Should compulsory screening of immigrants be part of UK public health policy?
10. NIH grants support health disparities biomedical research
11. NCCAM awards planning grants for International Centers for Research

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/14/2019)... ... 2019 , ... GreenTheVoteOk , one of the most reliable online resource ... the most relevant and important developments in the fast-changing world of legalized CBD. ... people across the world suffering from different difficult-to-treat ailments, people need to identify brands ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace injuries cost ... to solve injury risks which lead to musculoskeletal disorders (MSDs). , Starting ... by the team at Soter Analytics helps avoid ergonomic injury by ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... September 11-14 in Minneapolis at the Mall of America Radisson Blu. Four experts ... faculty members for the high-profile, knee-focused conference, which brings together more than 100 ...
(Date:9/11/2019)... ... 2019 , ... Autopsies don’t lie. They report the causes of death ... permanently harms the heart. It increases risks of heart attack and death. ... the damage occurs. , An August 1, 2019 article in U.S. ...
(Date:9/11/2019)... ... September 11, 2019 , ... Executives at health systems ... change in the healthcare industry over the past several years has been intense. For ... The future of healthcare in America will depend largely on how these executives respond. ...
Breaking Medicine News(10 mins):
(Date:9/18/2019)... ... September 18, 2019 , ... Henry Ford e-Home ... care via Henry Ford’s e-Home Care program. Achieving monthly readmission rates as low ... for the first six months of 2019 by 45% compared with the prior ...
(Date:9/18/2019)... ... September 18, 2019 , ... U.S. Dermatology Partners was ... water swim Saturday, September 14th. The event took place at Lake Ray Hubbard ... and Jim Montgomery. The money raised helps fund phase 1 clinical trials ...
(Date:9/17/2019)... ... September 17, 2019 , ... ... new, more effective therapeutic agents to stop the progressive destruction of joint cartilage ... have dawned, says Miami-based hand and upper limb orthopedic surgeon Alejandro Badia, ...
Breaking Medicine Technology:
Cached News: